Breakthrough in Gastric Cancer Treatment: Researchers Develop Effective Nanoparticle Therapy

Strategic Insights -

Researchers from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University have made a significant breakthrough in treating gastric cancer. The team, led by Xiaoyan Mao, discovered that a novel nanoparticle platform targeting the SLC6A14 (ATB) transporter can effectively inhibit gastric cancer cell proliferation in vitro and in vivo. This innovative approach provides a promising new therapeutic strategy for gastric cancer.

Key Takeaways:

  • Researchers developed an amino acid transporter-targeted nanoplatform (F/C@Trp-NPs) co-loaded with 5-fluorouracil (5-FU) and cryptotanshinone (Cpt) to target the SLC6A14 (ATB) transporter, which is abnormally upregulated in gastric cancer cells.
  • The F/C@Trp-NPs significantly inhibited gastric cancer cell proliferation in vitro and in vivo, consistent with the in vivo results.
  • The nanoplatform targets the STAT3-ferroptosis regulatory axis, which is a unique mode of regulated cell death characterized by iron accumulation and lipid peroxidation, contributing to chemotherapy resistance.
  • The study provides a promising new therapeutic strategy for gastric cancer, with the potential to overcome chemotherapy resistance.
  • The researchers developed a novel amino acid transporter-targeted nanoplatform that can enhance the delivery efficiency of chemotherapeutics.

Statistics:

  • 5-fluorouracil (5-FU) is a commonly used chemotherapeutic agent for gastric cancer treatment.
  • SLC6A14 (ATB) transporter is abnormally upregulated in gastric cancer cells, making it a potential target for therapeutic intervention.
  • The F/C@Trp-NPs demonstrated significant anticancer effects in both in vitro and in vivo studies.
  • The STAT3-ferroptosis regulatory axis is a unique mode of regulated cell death that is associated with chemotherapy resistance in gastric cancer.

Sources:

  • ATB0,+-targeted nanoparticles trigger STAT3-ferroptosis regulatory axis for enhanced gastric cancer therapy. Colloids and Surfaces B-biointerfaces, 2025;255:114918.
  • NewsRx. Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Reports Findings in Gastric Cancer (ATB0,+-targeted nanoparticles trigger STAT3-ferroptosis regulatory axis for enhanced gastric cancer therapy). Nanotechnology Weekly. July 14, 2025; p 1412.